Copeptin levels are more elevated and associated with cardiovascular events in the unity of chronic ischemic heart and chronic kidney diseases

Authors : Naci BABAT

Pages : 859-864

Doi:10.5798/dicletip.850390

View : 26 | Download : 22

Publication Date : 2020-12-30

Article Type : Research Paper

Abstract :Objective: Copeptin comprises the C-terminal part of the Arginine vasopressin (AVP) precursor, is co-secreted with AVP and is a stable surrogate marker for AVP release, making it much easier to measure. Elevated levels of serum copeptin in both cardiovascular and renal diseases were known but the amount and predictive value of copeptin in the unity of these diseases is unknown. Methods: A study composed equally divided five groups, total of 150 adult patients. Group I and group II composed study groups which included the patients of chronic ischemic heart (CHID) and chronic kidney diseases (CKD) respectively. Control groups such as group III, IV and V included only patients of CHID or CKD. Copeptin, hs-CRP and pro-BNP levels were analyzed in all patients and their relationship with adverse outcomes were evaluated. Results: Serum levels of copeptin, hs-CRP and pro-BNP were higher in patients of study groups than patients of control groups and it was found statistically meaningful (p<.05). Cardiovascular and all-cause mortality which defined as primary end points were similar in study and control groups but secondary end points such as re-hospitalization (p=.001 for group I and p=.026 for group II) and arrhythmias (p=.003 for group I and p=.001 for group II) were higher in the patients of study group. Conclusion: More elevated levels of copeptin in patients of study group couldn’t predict primary end points but it predicts some of secondary end points such as re-hospitalization and arrhythmias.
Keywords : copeptin, chronic kidney disease, chronic ischemic heart disease